Delivery Order SPE2DR25D3014-SPE2DR26FP1PG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,710.68 to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) on January 7, 2026, for the supply of Zepbound 10 mg/0.5 mL pens. This competitive, firm fixed-price delivery order is scheduled for ultimate completion on January 8, 2026, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order under Amerisourcebergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $18,939.21 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 ml pen injections, with a completion date of January 2, 2026. This is a firm fixed price, non-set-aside contract awarded on December 31, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $2,754.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on January 12, 2026, with an ultimate completion date of January 13, 2026. The contract was performed at the vendor's corporate office location in Conshohocken, Pennsylvania, and was awarded on a competitive, non-set-aside basis. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $42,193.95 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on December 15, 2025, with completion expected by December 16, 2025. This is a firm fixed price, non-set-aside contract with performance based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical...
- The Defense Logistics Agency awarded a $14,518.84 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pens on July 15, 2025, with completion scheduled for July 16, 2025. This competitive award carries firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply services under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $4,058.35 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on December 4, 2025, with completion expected by December 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound 5 mg/0.5 ml pens valued at $3,647.57. This firm fixed-price delivery order, with an ultimate completion date of July 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. The delivery order falls under the company's broader Indefinite Delivery...
- The Defense Logistics Agency awarded a $30,444.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pens on November 18, 2025, with completion scheduled for November 19, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement valued through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens at a ceiling value of $1,525.20. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with performance to be completed by July 1, 2025, with fulfillment occurring at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order falls under the company's larger Indefinite Delivery Contract...
- SPE2DR25D3014Indefinite Delivery Contract
- SPE2DR25D3014-SPE2DR26FP1PGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,570.92 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on January 12, 2026, with an ultimate completion date of January 13, 2026. This is a firm fixed-price, non-set-aside contract with performance based in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.999 billion through December 31, 2031, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical federal vendor specializing in supplying a comprehensive range of medications and medical commodities to military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill competitive procurements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices. This particular delivery order for Zepbound, a diabetes medication, exemplifies the company's role in supporting the Defense Health Agency and other government healthcare systems through flexible and efficient contract vehicles designed to meet military medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.6k | 1/11/26 |